Researchers found that fatty pancreas was observed to vary in different populations. The study published in the European ...

A recent study has found that nearly 54% of patients with type 2 diabetes (T2D) suffer from fatty pancreas disease (FPD).

Intermittent fasting has gained popularity among individuals who want to lose weight. While this approach has shown promising results, it may not be the best eating plan for everyone. When discussing ...

March 20 () - Taking GLP-1 drugs for diabetes has been shown to lower the risk of adverse heart events, but a new analysis ...

Nearly half of patients with T2D have micronutrient deficiencies, with vitamin D deficiency affecting 60.45% of patients. Women with T2D show a higher prevalence of micronutrient deficiencies compared ...

GLP-1 receptor agonist use in adults with concurrent type 2 diabetes and obesity was associated with increased risk for ...

Lilly’s experimental drug met endpoints for blood-sugar level reduction and weight loss at trial.

NHANES 2017–2018 elastography data (n=4102) linked to mortality showed 59 deaths over ~24 months; decedents were older and more likely to have diabetes. MASLD (CAP ≥274 dB/m) with diabetes carried ...

Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.

Glenmark Pharmaceuticals has announced the launch of GLIPIQ (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM), positioning it as a more affordable GLP-1 therapy aimed at ...

Adults with diabetes had an elevated risk for dementia, with a higher risk among those with type 1 compared with type 2 diabetes, according to a study published in Neurology.“Diabetes mellitus is well ...